Advances in radiation oncology · 2026
High-Dose Carbon Ion Reirradiation for Recurrent Pelvic Sarcomas: A Retrospective Analysis of Oncologic Outcomes in a Referral Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chalaszczyk Agnieszka, Ferrari Elettra Dorotea, Rotondi Marco, Molinelli Silvia, Barcellini Amelia, Vitolo Viviana, Fontana Giulia, Scardo Sara, Magro Giuseppe, Bazani Alessia, Ciocca Mario, Orlandi Ester, Fiore Maria Rosaria
Аннотация
PURPOSE: This study aims to evaluate the safety and efficacy of high-dose carbon ion reirradiation (CIR) in patients with recurrent pelvic sarcomas.
METHODS AND MATERIALS: This retrospective study included 46 patients treated with high-dose CIR for locoregional recurrences of pelvic sarcomas between 2013 and 2023 at the National Center for Oncological Hadrontherapy, Pavia, Italy. Clinical outcomes, toxicity, and cumulative doses were analyzed.
RESULTS: The median prescribed total dose of CIR was 60 GyRBE (range, 45-73.6 GyRBE). The maximum cumulative equivalent dose in 2 Gy fractions to the target volume reached 284 Gy, with a median of 153 Gy. The median follow-up was 32.5 months. The 1-, 2-, and 3-year locoregional progression-free survival rates were 79.1%, 43.9%, and 25.1%, respectively, with a mean time to locoregional relapse of 18.9 months. The 1-, 2-, and 3-year overall survival rates were 100%, 93.9%, and 83.1%, respectively. At last follow-up, grade 3 neuropathy occurred in 6.5% of the patients, grade 3 anorectal dysfunction in 8.7%, and grade 3 skin toxicity in 6.5%.
CONCLUSIONS: High-dose CIR is a feasible salvage strategy for recurrent pelvic sarcoma, offering promising outcomes and manageable toxicity in carefully selected patients. Prospective studies are warranted to refine dose-response models and validate long-term efficacy.
METHODS AND MATERIALS: This retrospective study included 46 patients treated with high-dose CIR for locoregional recurrences of pelvic sarcomas between 2013 and 2023 at the National Center for Oncological Hadrontherapy, Pavia, Italy. Clinical outcomes, toxicity, and cumulative doses were analyzed.
RESULTS: The median prescribed total dose of CIR was 60 GyRBE (range, 45-73.6 GyRBE). The maximum cumulative equivalent dose in 2 Gy fractions to the target volume reached 284 Gy, with a median of 153 Gy. The median follow-up was 32.5 months. The 1-, 2-, and 3-year locoregional progression-free survival rates were 79.1%, 43.9%, and 25.1%, respectively, with a mean time to locoregional relapse of 18.9 months. The 1-, 2-, and 3-year overall survival rates were 100%, 93.9%, and 83.1%, respectively. At last follow-up, grade 3 neuropathy occurred in 6.5% of the patients, grade 3 anorectal dysfunction in 8.7%, and grade 3 skin toxicity in 6.5%.
CONCLUSIONS: High-dose CIR is a feasible salvage strategy for recurrent pelvic sarcoma, offering promising outcomes and manageable toxicity in carefully selected patients. Prospective studies are warranted to refine dose-response models and validate long-term efficacy.